Vista previa | Fecha de publicación | Título | Autor(es) | Acceso |
![OPRM1 influence on and effectiveness of an individualized.pdf.jpg](/jspui/retrieve/f0912f0d-190d-4252-9401-6e74eb01cbdc/OPRM1%20influence%20on%20and%20effectiveness%20of%20an%20individualized.pdf.jpg) | 2018 | OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients | Muriel, Javier; Margarit, César; Planelles, Beatriz; Serralta, María J.; Puga, Carmen; Inda, María del Mar; Cutillas, Esperanza; Morales, Domingo; Horga, José F. | ![](/image/closedAccess.png) |
![Oxycodonenaloxone - naloxone versus tapentadol in real-world chronic non-cancer pain management.an observational and pharmacogenetic study.pdf.jpg](/jspui/retrieve/49e3f51c-59c2-43d1-9d15-6d348e3d5cf2/Oxycodonenaloxone%20-%20naloxone%20versus%20tapentadol%20in%20real-world%20chronic%20non-cancer%20pain%20management.an%20observational%20and%20pharmacogenetic%20study.pdf.jpg) | jun-2022 | Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study | Barrachina, Jordi; Margarit, César; Muriel, Javier; López‑Gil, Santiago; López Gil, Vicente; Vara-González, Amaya; Planelles, Beatriz; Inda, María del Mar; Morales, Domingo; Peiró, Ana | ![](/image/openAccess.png) |
![Oxycodonenaloxone.naxolone versus tapentadol in real world chronic non‑cancer pain.pdf.jpg](/jspui/retrieve/6dff66a3-3891-4c74-9646-8c79f0d0e88e/Oxycodonenaloxone.naxolone%20%20versus%20tapentadol%20in%20real%20world%20chronic%20non%e2%80%91cancer%20pain.pdf.jpg) | 2022 | Oxycodone/naloxone versus tapentadol in real‑world chronic non‑cancer pain management: an observational and pharmacogenetic study | Barrachina, Jordi; Margarit, Cesar; Muriel, Javier; López‑Gil, Santiago; López Gil, Vicente; Vara-González, Amaya; Planelles, Beatriz; Inda, María del Mar; Morales, Domingo; Peiró, Ana María | ![](/image/openAccess.png) |
![Pharmacogenetics and prediction of adverse events in.pdf.jpg](/jspui/retrieve/57275c95-8b6e-4e03-a7db-9b305d1d5d13/Pharmacogenetics%20and%20prediction%20of%20adverse%20events%20in.pdf.jpg) | 2018 | Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients | Muriel, Javier; Margarit, César; Barrachina, Jordi; Ballester, Purificación; Flor, Andrea; Morales, Domingo; Horga, José F.; Fernández, Eduardo; Peiró, Ana | ![](/image/closedAccess.png) |